EBOVAC3 | Bringing a prophylactic Ebola vaccine to licensure

Summary
The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:

“A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.”
Resources Show all and search (17)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/800176
Start date: 01-06-2018
End date: 30-09-2024
Total budget - Public funding: 50 979 889,00 Euro - 29 402 655,00 Euro
Cordis data

Original description

The overall aim of EBOVAC3 is to support an essential part of remaining clinical and manufacturing activities required for licensure in the European Union (EU) and the United States (US) of a candidate heterologous prime-boost prophylactic vaccine regimen against Ebola virus disease that is under development at Janssen Vaccines & Prevention B.V. The intended target indication is defined as:

“A prime-boost regimen with Ad26.ZEBOV as prime vaccine and MVA-BN®-Filo as boost vaccine indicated for the prevention of Ebola virus disease (EVD) caused by EBOV of the Zaire ebolavirus species in adults and elderly (aged ≥65 years), human immunodeficiency virus (HIV)-infected adults, and children aged ≥1 year.”

Status

SIGNED

Call topic

IMI2-2015-08-01

Update Date

26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-08-single-stage
IMI2-2015-08-01 Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
H2020-EU.3.1.7.0. Cross-cutting call topics
H2020-JTI-IMI2-2015-08-single-stage
IMI2-2015-08-01 Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks
Search
Search on Google
Search on Bing
Search on DuckDuckGo
Organisations
Show all (10)
Powered by Chris Decubber BV